Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

So far in 2025, the year’s biggest cultural events have served as launchpads for several of the industry's latest cancer ...

After a thorough review of the options trading surrounding Eli Lilly, we move to examine the company in more detail. This includes an assessment of its current market status and performance.

Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...

After a thorough review of the options trading surrounding Eli Lilly, we move to examine the company in more detail. This includes an assessment of its current market status and performance.

As a result, it will be available only on private prescription at a cost of €215 or more a month. That equates to an annual ...

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

Health insurers will not be covering the cost of a new obesity medication coming on to the market in Ireland. Mounjaro, a ...

Eli Lilly expects to provide results from a study in people with obesity and osteoarthritis of the knee in 2025.

Tirzepatide will be available at pharmacies in Ireland initially in doses of 2.5 mg and 5 mg, with availability of higher ...

Eli Lilly has begun the week with a bang. Early Monday morning, AdvanCell and OliX Pharmaceuticals put out news that the Big Pharma is coughing up cash to work with them on radiopharmaceuticals ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other long term low risk stocks. As the DeepSeek craze ignites a sell-off in the tech ...